SCHEMBL25804686

SCHEMBL25804686

Cc1ccc(CC(O)C(=O)O)cc1O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM6B O15054 1/20 0.72
ALOX15 P16050 5/20 0.47
KDM4E B2RXH2 4/20 0.47
HIF1A Q16665 4/20 0.47
HSD17B10 Q99714 4/20 0.47
RECQL P46063 3/20 0.47
TDP1 Q9NUW8 3/20 0.47
USP2 O75604 2/20 0.47
ADORA3 P0DMS8 2/20 0.47
HTR2A P28223 2/20 0.47
PTGS2 P35354 2/20 0.47
PTGS1 P23219 2/20 0.47
SLC7A5 Q01650 2/20 0.47
EGFR P00533 1/20 0.47
LCK P06239 1/20 0.47
FYN P06241 1/20 0.47
MME P08473 2/20 0.44
ACE P12821 2/20 0.44
PLA2G1B P04054 1/20 0.43
ALOX12 P18054 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2029160 0.86 KDM6B (0.72) KDM6BALOX15KDM4EHIF1AHSD17B10
SCHEMBL5691448 0.84 KDM6B (1.00) KDM6BALOX15KDM4EHIF1AHSD17B10
SCHEMBL29869020 0.84 KDM6B (1.00) KDM6BALOX15KDM4EHIF1AHSD17B10
SCHEMBL29350434 0.84 KDM6B (1.00) KDM6BALOX15KDM4EHIF1AHSD17B10
SCHEMBL829784 0.84 KDM6B (1.00) KDM6BALOX15KDM4EHIF1AHSD17B10
SCHEMBL18469325 0.84 KDM6B (1.00) KDM6BALOX15KDM4EHIF1AHSD17B10
SCHEMBL12406009 0.83 KDM6B (0.49) KDM6BALOX15KDM4EHIF1AHSD17B10
SCHEMBL29085429 0.82 KDM6B (0.96) KDM6BALOX15KDM4EHIF1AHSD17B10
SCHEMBL29085430 0.82 KDM6B (0.96) KDM6BALOX15KDM4EHIF1AHSD17B10
SCHEMBL6535013 0.82 KDM6B (0.96) KDM6BALOX15KDM4EHIF1AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11717549-B2 Steviol glycoside solubility enhancers CARGILL, INCORPORATED (US) 2023-08-08 US disclosed
US-11701400-B2 Steviol glycoside compositions with reduced surface tension CARGILL, INCORPORATED (US) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11701400-B2 Steviol glycoside compositions with reduced surface tension STT3A, SIGLEC7, STT3B KDM6B 4245/4885ALOX15 4388/4885KDM4E 4391/4885
US-11717549-B2 Steviol glycoside solubility enhancers SI, TAS2R7, TAS2R31 KDM6B 2458/4885ALOX15 2972/4885KDM4E 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.